CA-SIRIUS-THERAPEUTICS
2.2.2024 05:01:26 CET | Business Wire | Press release
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ and Ogury Collaborate to Enhance Media Planning and Audience Strategy with GeoPurchase Insights18.6.2026 12:00:00 CEST | Press release
New initiative brings real-world retail purchase signals into Ogury’s Persona Intelligence Engine to deliver deeper, privacy preserving insights across North America and Europe NIQ (NYSE: NIQ), the world’s leading consumer intelligence company, today announced a new collaboration with Ogury, the global AdTech company powered by Persona Intelligence. Through the collaboration, Ogury will integrate NIQ’s GeoPurchase data into its Persona Intelligence Engine, strengthening audience planning, media activation, and strategic insights for marketers. NIQ delivers world-leading retail intelligence, capturing actual purchase data at the product level across key retailers around the world. Through this collaboration, NIQ is providing GeoPurchase insights at scale across France, Germany, Spain, Italy, the UK, as well as the United States and Canada, bringing a new layer of real-world retail purchase behavior into Ogury’s Persona Intelligence Engine. Combined with Ogury’s audience-first data model
Linvo Sets Sights on AI-Led Wealth Management, Opens AI Advisor Roles for 202618.6.2026 11:40:00 CEST | Press release
Linvo AG, a Zurich-based multi-family office and wealth management firm, today set out its vision for the year ahead, naming applied artificial intelligence as the centre of its strategy for 2026 and opening a new set of AI advisor roles to deliver it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618933521/en/ Linvo sets sights on AI-led wealth management, opens AI advisor roles for 2026 The firm sees the coming year as the point at which AI moves from a support tool to a core discipline within wealth management — shaping how portfolios are analysed, how clients are served, and how advisory teams spend their time. The new AI advisor roles are intended to anchor that shift inside the firm. "2026 is the year we stop treating AI as an add-on and start treating it as a discipline in its own right," said Alexander Kogan, Director at Linvo. "Hiring AI advisors is how we build that future deliberately, rather than leaving it t
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 10:31:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
Infobip Ranked in Top 25 of Fortune's Europe's Most Innovative Companies 202618.6.2026 10:11:00 CEST | Press release
A strong result highlighting Infobip’s momentum in European tech innovation Global AI-first cloud communications platform Infobip has been ranked in the top 25 of Fortune's Europe's Most Innovative Companies 2026, marking a strong rise on this year's list. The announcement was made at VivaTech in Paris. Last year, Infobip entered Fortune's inaugural ranking at number 68. This year, it climbs to 16! The Fortune Europe's Most Innovative Companies list, in partnership with the global research firm Statista, evaluates companies based on innovation culture, product development, and process improvements. Infobip's rise reflects the accelerating momentum behind its AI-first strategy, including the launch of Infobip AgentOS, its AI-native fully managed solution that orchestrates autonomous AI-driven customer journeys at scale. Infobip's innovation credentials are further reinforced by its role in Important Project of Common European Interest (IPCEI) for Next Generation Cloud Infrastructure and
Philip Morris International Announces New Regional Leadership18.6.2026 10:00:00 CEST | Press release
The appointments strengthen the company’s leadership pipeline as it moves towards a smoke‑free future Philip Morris International (PMI) (NYSE: PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future. Effective August 1, 2026, Marco Hannappel has been appointed President, Europe Region, and Can Kuterdem has been appointed President, Latin America & Canada Region. These appointments build on PMI’s evolved organizational model announced in late 2025, under which Gijs de Best serves as President, South Asia, Indochina, CIS & Middle East & Africa Region, and Vassilis Gkatzelis continues as President East & Southeast Asia, Pacific and PMI Global Travel Retail Region. The four regional presidents report to Frederic de Wilde - CEO of the International Business Unit of PMI and are the key operational leaders for the unit that generates the large majority of total PMI net revenues. Marco Hannappel takes over the role of President, Euro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom